Bo Ahrén
51 – 60 of 393
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Effect of the GLP-1 Receptor Agonist Lixisenatide on Counter-Regulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
(
- Contribution to journal › Article
-
Mark
Decreased insulin secretion and glucose clearance in exocrine pancreas-insufficient pigs.
(
- Contribution to journal › Article
-
Mark
Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes : The adjunct two randomized trial
(
- Contribution to journal › Article
-
Mark
Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes
(
- Contribution to journal › Article
-
Mark
Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus : A Post Hoc Analysis
(
- Contribution to journal › Article
-
Mark
Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation
(
- Contribution to journal › Article
-
Mark
Extrapancreatic contribution to glucose regulation by dipeptidyl peptidase 4 inhibition
(
- Contribution to journal › Scientific review
-
Mark
Defective insulin secretion by chronic glucagon receptor activation in glucose intolerant mice.
(
- Contribution to journal › Article
-
Mark
Evidence for time dependent variation of glucagon secretion in mice.
(
- Contribution to journal › Article
-
Mark
CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion
(
- Contribution to journal › Article